Session date: 10/22/2025 - 12:00pm to 1:00pm

Speaker Bio:

Mark D. Tyson II, M.D. is a urologic oncologist specializing in bladder cancer, with clinical expertise in both muscle-invasive and non-muscle invasive disease. His practice includes advanced surgical approaches—robotic, open, and single-port cystectomy—as well as urinary diversion techniques such as ileal conduits and orthotopic neobladders. He also offers intravesical therapies, utilizes blue light cystoscopy for enhanced detection, and is dedicated to improving quality of life outcomes for patients with bladder cancer.  In addition to his clinical practice, Dr. Tyson is actively engaged in research and education, regularly publishing in scientific journals and mentoring trainees. He is currently leading and recruiting for multiple clinical trials aimed at advancing treatment for bladder cancer, including studies investigating novel therapies such as TAR-200, CG0070, pembrolizumab, enfortumab vedotin, and TARA-002. These trials explore innovative strategies ranging from urine-based molecular testing for surveillance to chemoablation and immune-based therapies for BCG-naïve and BCG-unresponsive patients

Learning Objectives
Upon completion of this activity, participants should be able to:

1. Review the historical timeline of FDA approvals

2.  Explain the clinical need that emerging agents aim to address.

3.  Describe the mechanisms of action, administration routes, and safety profiles of novel intravesical therapies including cretostimogene, nadofaragene, TAR-200, and Nogapendekin

4. Compare efficacy outcomes (CR rate, DoR) and adverse event profiles across approved and investigational therapies to support informed clinical decision-making

5. Identify appropriate candidates for novel therapies, especially in the context of BCG-unresponsive disease, and discuss considerations in selecting between bladder-sparing treatment and cystectomy

ATTENDANCE / CREDIT

Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.